Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Macrosalb→

Macrosalb Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
54182-63-7
Molecular formula
Not available
Molecular weight
Not available
Drug class
Diagnostic radiopharmaceutical precursorhuman serum albumin macroaggregates for technetium-99m labelling
Mechanism of action
Albumin macroaggregate particles, when labelled with technetium-99m, are trapped transiently in pulmonary capillaries and arterioles in proportion to regional blood flow. The resulting distribution of gamma emissions permits scintigraphic assessment of pulmonary perfusion.
Indications / reported uses
  • After radiolabelling with technetium-99m, used for lung perfusion scintigraphy as an adjunct in evaluation of pulmonary perfusion in adults and children.
  • After radiolabelling, can be used for peritoneovenous shunt scintigraphy to assess shunt patency in adults, according to the product label.

Sources: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=a8b7adf0-2c6b-4acd-96d3-a099306951a0 · https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210089s002lbl.pdf · https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-core-summary-products-characteristics-smpc-and-package-leaflet-technetium-99mtc-macrosalb_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Macrosalb Environmental Risk Assessment (ERA) (the Macrosalb ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.